Jco precision oncology.
The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ...
DOI: 10.1200/PO.20.00516 JCO Precision Oncology no. 5 (2021) 653-663. Published online April 13, 2021. Published online April 13, 2021. MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and …WebSep 13, 2017 · The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ... In this prospective, case-control study, we assessed the performance of a blood-based multi-cancer detection test to detect cancer and predict the origin of the cancer signal in individuals with symptoms suspicious for cancer.Aims & Scope of the Journal. JCO Precision Oncology publishes academic articles describing recent essential contributions in the areas of Biological Sciences, General …The analysis focuses on the independent and cumulative impacts of gaps occurring during seven steps of the precision oncology pathway, from diagnosis to treatment. Results: For every 1,000 patients in the study cohort, 497 (49.7%) are lost to precision oncology because of factors associated with getting biomarker test results. Among the 503 of ...
Limit the abstract to 275 words and place it after the title page. Do not use proprietary or trade names in the title or abstract. Case Reports, Commentaries, Editorials, and Correspondence articles do not require abstracts. Write the body of the manuscript as concisely as possible.PURPOSE Precision medicine uses advanced molecular techniques to guide the use of targeted therapeutic drugs and is an emerging paradigm in pediatric oncology. Clinical evidence related to the efficacy of many novel targeted drugs, however, is currently very limited given the rarity of pediatric cancer and the lack of published evidence for the use of these drugs in children. This systematic ...JCO PO recognizes that a practice-changing manuscript may have undergone prior peer review by a highly regarded oncology or cancer research journal, but it was not …
DOI: 10.1200/PO.21.00011 JCO Precision Oncology no. 5 (2021) 1687-1698. Published online November 3, 2021. Published online November 3, 2021. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown PrimaryPatient-level clinical and ctDNA data were pooled and harmonized from 200 patients across five independent clinical trials investigating the treatment of patients with non–small-cell lung cancer with programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)–directed monotherapy or in combination with chemotherapy.
DOI: 10.1200/PO.21.00108 JCO Precision Oncology no. 5 (2021) 1151-1159. Published online July 15, 2021. Published online July 15, 2021. Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-AnalysisPrecision fabrication is a critical process in various industries, including manufacturing, construction, and automotive. Whether it’s building structures, creating intricate metal designs, or repairing equipment, welding plays a crucial ro...Apr 1, 2021 · Multicancer Screening: One Size Does Not Fit All. Cancer is the second leading cause of death in the United States, 1 and early detection represents one of the best hopes for reducing cancer-associated morbidity and mortality. However, current screening strategies are limited by suboptimal adherence, low sensitivity for early-stage disease ... Final Summary · The impact factor of JCO Precision Oncology is 5.479. · The JCO Precision Oncology is a reputed research journal. · It is published by ...Mar 19, 2021 · DOI: 10.1200/PO.20.00321 JCO Precision Oncology no. 5 (2021) 510-524. Published online March 19, 2021. Published online March 19, 2021. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy
The analysis focuses on the independent and cumulative impacts of gaps occurring during seven steps of the precision oncology pathway, from diagnosis to treatment. Results: For every 1,000 patients in the study cohort, 497 (49.7%) are lost to precision oncology because of factors associated with getting biomarker test results. Among the 503 of ...Web
DOI: 10.1200/PO.20.00008 JCO Precision Oncology no. 4 (2020) 393-410. Published online April 23, 2020. PMID: 35050740. Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non–Small-Cell Lung Cancer With Rare or Complex Mutational Profiles ...
DOI: 10.1200/PO.20.00504 JCO Precision Oncology no. 6 (2022) e2000504. Published online January 27, 2022. PMID: 35085008. Improved Gene Fusion Detection in Childhood Cancer Diagnostics Using RNA Sequencing Jayne Y. Hehir-Kwa, PhD 1. x. Jayne Y. Hehir-Kwa. Search for articles by this author ...A fellow M.D. is a medical doctor who has been given a fellowship, which is a residency that teaches doctors a sub-specialty, such as internal medicine, movement disorders, gynecologic oncology and pediatric hematology, according to the Uni...DOI: 10.1200/PO.20.00504 JCO Precision Oncology no. 6 (2022) e2000504. Published online January 27, 2022. PMID: 35085008. Improved Gene Fusion Detection in Childhood Cancer Diagnostics Using RNA Sequencing Jayne Y. Hehir-Kwa, PhD 1. x. Jayne Y. Hehir-Kwa. Search for articles by this author ...OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions. DOI: 10.1200/PO.21.00535 JCO Precision Oncology no. 6 (2022) e2100535. Published online May 11, 2022. PMID: 35544728. Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer Hideaki Bando, MD 1, 2. x. Hideaki Bando. Search for articles by this author ...WebKey Objective. To improve identification of hereditary cancer syndromes in individuals with colorectal cancer (CRC), a statewide initiative was created to provide universal tumor screening for Lynch syndrome (LS) for 3,310 unselected patients with CRC (the largest cohort to date) and to provide germline pan-cancer multigene panel testing to selected patients with CRC to assess frequency and ...DOI: 10.1200/PO.18.00325 JCO Precision Oncology - published online June 13, 2019
Key Objective. To improve identification of hereditary cancer syndromes in individuals with colorectal cancer (CRC), a statewide initiative was created to provide universal tumor screening for Lynch syndrome (LS) for 3,310 unselected patients with CRC (the largest cohort to date) and to provide germline pan-cancer multigene panel testing to selected patients with CRC to assess frequency and ...PURPOSE In prostate cancer, inactivating CDK12 mutations lead to gene fusion–induced neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically, pathologically, and molecularly characterize CDK12-aberrant prostate cancers. METHODS We conducted a retrospective multicenter study to identify patients with advanced prostate cancer who harbored somatic loss-of-function CDK12 ...JCO Precision Oncology, 2022 Aug 11. PMID: 35952319; Storrs EP, Usmani A, Chati P, Sloan I, Krasnick BA, Babbra R, Harris PK, Qaium F, Chatterjee D, Wetzel C ...DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 AlterationsWebInitiative for Molecular Profiling and. Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis. Oncol 2017;2017.. [5] Le Tourneau ...
Although precision oncology is transforming clinical management of patients with cancer, many hospitals face challenges to effectively implement precision oncology. In addition, the cost and time exerted for genomic profiling needs to be balanced with expectations of benefit for each patient. ... JCO Precis Oncol. 2019 Dec …Lung cancer is the leading cause of cancer-related death worldwide. Non–small-cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases, 1 is a group of heterogeneous diseases driven by a spectrum of molecular alterations. Targeted therapies directed toward specific molecular alterations, such as a mutation in epidermal …
By July 20, 2020, 20 patients with TRK fusion–positive lung cancer had been treated. The ORR by investigator assessment among 15 evaluable patients was 73% (95% CI, 45 to 92); one (7%) patient had a complete response, 10 (67%) had a partial response, three (20%) had stable disease, and one (7%) had progressive disease as best response. JCO Precision Oncology, published online May 14, 2018. https://ascopubs.org/doi/full/10.1200/PO.17.00247. Thyroid Cancer. Busaidy NL, Konda B, Wei L, Wirth LJ ...Purpose Appendiceal neoplasms are heterogeneous and are often treated with chemotherapy similarly to colorectal cancer (CRC). Genomic profiling was performed on 703 appendiceal cancer specimens to compare the mutation profiles of appendiceal subtypes to CRC and other cancers, with the ultimate aim to identify potential biomarkers …Apr 22, 2021 · PURPOSE CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and ... DOI: 10.1200/PO.20.00241 JCO Precision Oncology no. 5 (2021) 93-102. Published online January 11, 2021. PMID: 34994593. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer ...JCO Precision Oncology. Published by American Society of Clinical Oncology. Online ISSN: 2473-4284. Top-cited authors. Debyani Chakravarty. Memorial Sloan Kettering …Purpose HER2 amplification has been implicated in resistance to therapy with anti–epidermal growth factor receptor antibodies (anti-EGFRabs) in metastatic colorectal cancer (mCRC). The purpose of the study was to validate the predictive impact of HER2 amplification in mCRC. Patients and Methods We analyzed patients with RAS/BRAF wild-type mCRC across two distinct cohorts. In cohort 1 (n = 98 ...Oct 6, 2022 · DOI: 10.1200/PO.22.00024 JCO Precision Oncology no. 6 (2022) e2200024. Published online October 6, 2022. PMID: 36201714
DOI: 10.1200/PO.17.00084 JCO Precision Oncology - published online October 3, 2017
PURPOSE The adoption of precision medicine (PMed) depends on the critical curation of data and interpretation of genomic results. Herein, we sought to study the effect of a coordinated multidisciplinary program to assess results in a community cancer center clinic. METHODS In a retrospective review from July 2018 to July 2021, we …
Given the high attrition rate of de novo drug discovery and limited efficacy of single-agent therapies in cancer treatment, combination therapy prediction through in silico drug repurposing has risen as a time- and cost-effective alternative for identifying novel and potentially efficacious therapies for cancer. The purpose of this review is to provide an introduction to computational methods ...31 Aug 2022 ... Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson Precision Medicine Study. JCO Precis. Oncol. 2017;2017.CHASTEPA metro station (2nd station), SCHOOL #303. A reliable partner for everyone who cares about their health. We offer a wide range of services, ranging from laboratory and …6 Nov 2023 ... jpg. Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer ...29 Sept 2022 ... Precision medicine in pediatric oncology. ... Improved gene fusion detection in childhood cancer diagnostics using RNA sequencing. JCO Precis ...By choosing this option you are agreeing to pay the article processing charge of $2,300 (Original Reports) or $792 (Case Reports). This will be billed after acceptance of your article. Open access requirements may vary depending on the source of funding for your submission. If you have questions regarding open access requirements, this guide to ... In this precision oncology era, where molecular profiling at the individual patient level becomes increasingly accessible and affordable, more and more clinical trials are now driven by biomarkers, with an overarching objective to optimize and personalize disease management. As compared with the conventional clinical development …JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...WebThis is the context motivating the publication by Stetson et al 10 in JCO Precision Oncology. The authors sent aliquots of plasma to four commercial Clinical Laboratory Improvement Amendments–certified laboratories for plasma NGS and compared this to NGS performed on matched tumor and normal tissue at Foundation Medicine. …PURPOSE Next-generation sequencing (NGS) of tumor and germline DNA is foundational for precision oncology, with rapidly expanding diagnostic, prognostic, and therapeutic implications. Although few question the importance of NGS in modern oncology care, the process of gathering primary molecular data, integrating it into electronic health …DOI: 10.1200/PO.23.00338 JCO Precision Oncology no. 7 (2023) e2300338. Published online December 1, 2023. Published online December 1, 2023. Homologous Recombination Deficiency Across Subtypes of …
Soft boiled eggs are a delicious and versatile dish that can be enjoyed for breakfast, lunch, or dinner. Cooking the perfect soft boiled egg requires precision and attention to detail.Precision oncology, where patients are given therapies on the basis of their genomic profile and disease trajectory, is rapidly evolving to become a pivotal part of cancer management, supported by the approval of many biomarker-matched targeted therapies and cancer immunotherapies by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). 1 Driven by recent advances in ...JCO Precision Oncology. Published by American Society of Clinical Oncology. Online ISSN: 2473-4284. Top-cited authors. Debyani Chakravarty. Memorial Sloan Kettering …Aug 19, 2021 · DOI: 10.1200/PO.20.00472 JCO Precision Oncology no. 5 (2021) 1312-1324. Published online August 19, 2021. Published online August 19, 2021. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples Instagram:https://instagram. forex vs stockswhy is gas prices going downare any quarters worth moneyanheuser busch modelo DOI: 10.1200/PO.18.00028 JCO Precision Oncology - published online October 19, 2018Web xpr stockge breakup DOI: 10.1200/PO.21.00002 JCO Precision Oncology no. 6 (2022) e2100002. Published online January 6, 2022. PMID: 35005994WebDOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations what is a kennedy 50 cent piece worth DOI: 10.1200/PO.20.00532 JCO Precision Oncology no. 5 (2021) 1241-1249. Published online August 5, 2021. Published online August 5, 2021. Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic ProfilingWebDOI: 10.1200/PO.20.00516 JCO Precision Oncology no. 5 (2021) 653-663. Published online April 13, 2021. Published online April 13, 2021. MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing ConsiderationsApr 1, 2021 · Multicancer Screening: One Size Does Not Fit All. Cancer is the second leading cause of death in the United States, 1 and early detection represents one of the best hopes for reducing cancer-associated morbidity and mortality. However, current screening strategies are limited by suboptimal adherence, low sensitivity for early-stage disease ...